Evidence map›Paper›PMID 37402749›Full record

ArticleScientific reports2023

Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.

Jung-Hoon Kim, Navin Pandit, Miyoun Yoo, Tae Hyun Park, Ji U Choi, Chi Hoon Park, Kwan-Young Jung, Byung Il Lee

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jung-Hoon Kim *Research Institute, National Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea.
Navin Pandit *Department of Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon, 34113, Republic of Korea.
Miyoun Yoo *Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, 34114, Republic of Korea.
Tae Hyun Park *Department of Anesthesiology, Weill Cornell Medical College, New York, NY, 10065, USA.
Ji U ChoiDepartment of Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon, 34113, Republic of Korea.
Chi Hoon ParkDepartment of Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon, 34113, Republic of Korea. chpark@krict.re.kr.
Kwan-Young JungDepartment of Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon, 34113, Republic of Korea. krjeong@krict.re.kr.
Byung Il LeeResearch Institute, National Cancer Center, Goyang, Gyeonggi, 10408, Republic of Korea. bilee@ncc.re.kr.
Korea University of Science and Technology · KRNational Cancer Center · KRCornell University · USKorea Research Institute of Chemical Technology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRD4 contains two tandem bromodomains (BD1 and BD2) that recognize acetylated lysine for epigenetic reading, and these bromodomains are promising therapeutic targets for treating various diseases, including cancers. BRD4 is a well-studied target, and many chemical scaffolds for inhibitors have been developed. Research on the development of BRD4 inhibitors against various diseases is actively being conducted. Herein, we propose a series of [1,2,4]triazolo[4,3-b]pyridazine derivatives as bromodomain inhibitors with micromolar IC

Indexed as

Nuclear ProteinsTranscription FactorsCell Cycle ProteinsProtein DomainsStructure-Activity RelationshipCell Cycle ProteinsNuclear ProteinsTranscription Factors

Identifiers

PMID37402749
PMCPMC10319850
OpenAlexW4383102982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.